Crescent Biopharma

Congratulations to Kelun-Biotech on receiving IND approval from China’s CDE for CR-001 (SKB118), an investigational PD-1 x VEGF bispecific antibody for the treatment of advanced solid tumors: https://bit.ly/4eK81pY    This is an important step in the global development of CR-001 (SKB118). We look forward to continuing to partner with Kelun-Biotech on our shared commitment to realize the full potential of CR-001 (SKB118) to be a best-in-class immuno-oncology backbone and advancing synergistic ADC combinations to improve outcomes with people living with cancer.

Today, Crescent is participating in a fireside chat at the Bank of America 2026 Healthcare Conference in Las Vegas. Register to tune in to the webcast at 4:20 p.m. PT/7:20 p.m. ET: https://bit.ly/3OZzp8X 

Meet Wenjie Cheng, Ph.D., who is the Senior Vice President of Technical Operations at Crescent, leading our CMC strategy and overseeing manufacturing operations. Wenjie brings more than 20 years of experience in the biopharmaceutical industry, with deep expertise in process development and manufacturing across antibody and antibody-drug conjugate (ADC) therapeutics. We’re thrilled to have her in this important role! #BiotechManufacturing #TeamCrescent 

Today Crescent reported first quarter 2026 financial results and recent business highlights. For details, read our press release: https://bit.ly/3OCgm4q

Crescent is growing – and we’re looking for people who want to help build what’s next in oncology.  If you’re driven by the opportunity to help deliver the next wave of transformative therapies and make a meaningful impact for patients, we’d love to hear from you.  Explore our open roles: https://lnkd.in/gQrhGRqK  #TeamCrescent 

Today, on #AdministrativeProfessionalsDay, we’re recognizing the incredible individuals behind the scenes who keep Crescent running.  Their thoughtfulness, coordination, and dedication to our team helps power the progress behind everything we do for patients.   Thank you for all that you do. #TeamCrescent 

Earlier this month, #TeamCrescent volunteered at Boston Hope Lodge, a program through American Cancer Society that offers a home away from home for patients and their families undergoing cancer treatment, cooking and sharing a meal together.  Experiences like this bring our mission to life and reinforce our culture centered on patients, community, and making a real impact.  

#CancerControlMonth was established in 1938 as a U.S. congressional effort to raise awareness of cancer prevention and early detection, an important focus that continues today. While early action can change outcomes, innovation remains critical for those living with cancer.  At Crescent, we’re focused on advancing the next generation of therapies to help bring a brighter future for patients.    #Oncology #CancerCare

Members of our team are looking forward to attending the American Association for Cancer Research Annual Meeting this year!  We’re excited to connect with the oncology community, discussing the latest advancements in scientific research. #AACR26

Congratulations to Kelun-Biotech on recently initiating a Phase 1/2 trial of CR-003 (SKB105) in patients with advanced solid tumors in China. CR-003 (SKB105) is a differentiated ADC targeting integrin beta-6 (ITGB6) with a topoisomerase 1 inhibitor payload. We are proud to be partnering with Kelun to advance next generation therapies that can improve outcomes for people living with cancer. Learn more about CR-003 here: https://bit.ly/4sFJS7P